UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The development of PARP inhibitors in ovarian cancer: from bench to bedside

British journal of cancer, 2015-12, Vol.113 Suppl 1 (S1), p.S3-S9

Drew, Yvette

2015

Volltextzugriff (PDF)

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Pharmacology & therapeutics (Oxford), 2020-03, Vol.207, p.107450-107450, Article 107450

2020

Volltextzugriff (PDF)

Targeting the ATR-CHK1 Axis in Cancer Therapy

Cancers, 2017-04, Vol.9 (5), p.41

2017

Volltextzugriff (PDF)

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Clinical cancer research, 2020-03, Vol.26 (6), p.1220-1228

2020

Volltextzugriff (PDF)

Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib

Gynecologic oncology reports, 2024-08, Vol.54, p.101439, Article 101439

2024

Volltextzugriff (PDF)

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma

Cancers, 2021-12, Vol.14 (1), p.14

2021

Volltextzugriff (PDF)

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

Cancers, 2020-07, Vol.12 (7), p.1939

2020

Volltextzugriff (PDF)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

Cancers, 2022-11, Vol.14 (22), p.5559

2022

Volltextzugriff (PDF)

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

Cells (Basel, Switzerland), 2022-08, Vol.11 (15), p.2361

2022

Volltextzugriff (PDF)

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

Cancers, 2021-03, Vol.13 (6), p.1420

2021

Volltextzugriff (PDF)

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

Cancers, 2019-03, Vol.11 (3), p.354

2019

Volltextzugriff (PDF)

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Clinical cancer research, 2009-02, Vol.15 (4), p.1241-1249

2009

Volltextzugriff (PDF)

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Blood advances, 2018-05, Vol.2 (10), p.1157-1169

2018

Volltextzugriff (PDF)

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

Cancer medicine (Malden, MA), 2018-09, Vol.7 (9), p.4744-4754

2018

Volltextzugriff (PDF)

Homologous recombination deficiency and ovarian cancer

European journal of cancer (1990), 2016-06, Vol.60, p.49-58

2016

Volltextzugriff (PDF)

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

Drug resistance updates, 2009-12, Vol.12 (6), p.153-156

2009

Volltextzugriff (PDF)

Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17547-e17547

2023

Volltextzugriff (PDF)

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53 WT Uterine Leiomyosarcoma

Cancers, 2021-12, Vol.14 (1)

2021

Volltextzugriff (PDF)

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Nature reviews. Clinical oncology, 2019-12, Vol.16 (12), p.725-726

2019

Volltextzugriff (PDF)

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors

Clinical cancer research, 2017-08, Vol.23 (15), p.4095-4106

2017

Volltextzugriff (PDF)

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

British journal of cancer, 2016-03, Vol.114 (7), p.723-730

2016

Volltextzugriff (PDF)

EP244/#277 Examining real-world treatment benefits of first-line maintenance niraparib in non-BRCA mutant high grade serous ovarian cancers

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A178-A178

2023

Volltextzugriff (PDF)

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

Cancer discovery, 2021-01, Vol.11 (1), p.80-91

2021

Volltextzugriff (PDF)

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

British journal of cancer, 2020-08, Vol.123 (4), p.525-533

2020

Volltextzugriff (PDF)

Abstract 1385: In vitro evaluation of platinum chemotherapy combinations with the ATR inhibitor, ceralasertib (AZD6738)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1385-1385

2020

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(84)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Humans
(31)
Oncology
(30)
Female
(22)
Ovarian Cancer
(19)
Middle Aged
(14)
Tumors
(14)
Aged
(13)
Mutation
(12)
Adult
(11)
Ovarian Neoplasms - Drug Therapy
(11)
Poly Polymerase
(11)
Chemotherapy
(10)
Brca2 Protein - Genetics
(9)
Ovarian Neoplasms - Genetics
(9)
Poly Polymerase Inhibitors
(9)
Breast Cancer
(8)
Dna Damage
(8)
Poly Polymerase Inhibitors - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The development of PARP inhibitors in ovarian cancer: from bench to bedside

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Targeting the ATR-CHK1 Axis in Cancer Therapy

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

Homologous recombination deficiency and ovarian cancer

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC)

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53 WT Uterine Leiomyosarcoma

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

EP244/#277 Examining real-world treatment benefits of first-line maintenance niraparib in non-BRCA mutant high grade serous ovarian cancers

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

Abstract 1385: In vitro evaluation of platinum chemotherapy combinations with the ATR inhibitor, ceralasertib (AZD6738)

Suchergebnisse filtern